PIOGLITAZONE
Clinical safety rating: safe
Animal studies have demonstrated safety
Selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), modulating transcription of genes involved in glucose and lipid metabolism, increasing insulin sensitivity in adipose tissue, muscle, and liver.
| Metabolism | Primarily metabolized by CYP2C8; hydroxylation and oxidation; minor pathways via CYP3A4; excreted in feces and urine. |
| Excretion | Primarily hepatic metabolism via CYP2C8 and CYP3A4; approximately 15-30% excreted in urine as metabolites, with the remainder in feces (~70%) via biliary elimination. Renal excretion of unchanged drug is negligible (<1%). |
| Half-life | Terminal elimination half-life is 3-7 hours in healthy adults, but extends to 16-24 hours in patients with hepatic impairment due to reduced clearance. Steady-state is achieved after 4-6 days of dosing. |
| Protein binding | Highly protein bound (>99%), primarily to albumin. |
| Volume of Distribution | Apparent volume of distribution (Vd/F) is 0.25 ± 0.1 L/kg, indicating distribution mainly in total body water with limited tissue binding. |
| Bioavailability | Absolute bioavailability is >80% (mean 83%) after oral administration, with food slightly delaying but not reducing absorption (AUC unchanged). |
| Onset of Action | Oral: Improvement in glycemic control begins within 2-4 weeks, with maximal effects on fasting plasma glucose and HbA1c observed after 6-12 weeks of therapy. |
| Duration of Action | Duration of action is approximately 24 hours, supporting once-daily dosing. Clinical effect persists for several days after discontinuation due to slow receptor dissociation. |
15-30 mg orally once daily; maximum dose 45 mg/day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. Not recommended for use in patients with ESRD on dialysis. |
| Liver impairment | Contraindicated in patients with Child-Pugh Class C hepatic impairment. Use with caution in Class A or B; no specific dose adjustment recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 15 mg once daily; no dosage adjustment required based on age alone, but consider renal function and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and bladder cancer.
| Breastfeeding | Pioglitazone is excreted in rat milk, but no human data available. M/P ratio not determined. Due to unknown excretion in human milk and potential for adverse effects in nursing infants (e.g., fluid retention), caution is recommended. Consider alternatives, especially when breastfeeding a preterm or low-weight infant. |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show delayed parturition, embryotoxicity, and increased fetal mortality in rats and rabbits at doses producing exposure levels similar to or greater than human therapeutic doses. Human data are limited; first trimester exposure not associated with major congenital malformations in small observational studies. Second and third trimester: risk of maternal hypoglycemia if used with insulin or sulfonylureas; potential for fetal macrosomia due to improved glycemic control. Avoid use in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
May cause or exacerbate congestive heart failure (CHF); not recommended in patients with symptomatic heart failure (NYHA Class III or IV).
| Common Effects | Headache Sore throat Sinus inflammation Muscle pain |
| Serious Effects |
["NYHA Class III or IV heart failure","Active bladder cancer or history of bladder cancer","Severe hepatic impairment (Child-Pugh Class C)","Known hypersensitivity to pioglitazone or any component"]
| Precautions | ["Congestive heart failure","Edema","Hepatic effects (monitor LFTs)","Bladder cancer risk (avoid in active bladder cancer)","Bone fractures in females","Ovulation in premenopausal anovulatory females (increased risk of pregnancy)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c regularly. Assess for signs of fluid retention (e.g., peripheral edema, weight gain) and hepatic function (ALT, AST) at baseline and periodically. Fetal monitoring includes ultrasound for growth and amniotic fluid volume (risk of macrosomia). In third trimester, monitor for hypoglycemia if used with other agents. No specific fetal heart rate monitoring required unless complications arise. |
| Fertility Effects | In animal studies, pioglitazone caused delayed ovulation and reduced implantation in rats at high doses. In women, improvement in insulin resistance and ovulatory function may occur, potentially increasing fertility in anovulatory PCOS patients. However, no formal human fertility studies. Caution in women attempting pregnancy due to unknown effects on early embryo development. |